News

Waltham, MA, based 3-D Matrix, Inc.’s parent company 3-D Matrix, Ltd., Tokyo, Japan, is currently traded on the JASDAQ [7777.OS]. Click here to be directed to 3-D Matrix, Ltd. investor relations page.

05 June 2014
Patent Granted in Europe on Use of Lipid-Like Self-Assembling Peptide Surfactant Technology as “Transfection Agent”

04 June 2014
Absorbable Hemostat “TDM-621” Product Registration Application Submitted in Singapore

30 May 2014
Patent Granted on “Pancreatic Regeneration” with Self-assemblinging Peptide Technology

12 May 2014
License Agreement on Self-Assembled Ultrashort Peptide Technology

02 April 2014
[Delayed] Patent Granted in Japan on “Wound Healing and Skin Regeneration Material”with Self-assembling Peptide Technology

14 March 2014
Revision of Forecast of Financial Results for FY2013

14 March 2014
Revision of Mid-term Business Plan (FY2013-FY2015)

10 March 2014
[Delayed] Notice Regarding Exercise Price of Share Warrants

24 February 2014
[Delayed] Issuance of Share Warrants

13 February 2014
Patent Granted in US on “Pancreatic Regeneration” with Self-assembling Peptide Technology

31 January 2014
MIT and 3-D Matrix, Inc. Files Patent Infringement Complaint Against Menicon Co. Ltd. and B-Bridge International Inc.

15 January 2014
Surgical Hemostat(TDM-621):CE Marking Certificate Issued

08 November 2013
[Delayed] 3-D Matrix Nominated in “COI STREAM Program”

31 May 2013
[Delayed] Partnership Agreement concluded with PT. Teguhsindo Lestaritama regarding sales and marketing of surgical hemostat (TDM-621) in Indonesia

28 May 2013
[Delayed] Patent Granted on “Hepatic and Pancreatic Regeneration” with Self-assembling Peptide Technology

21 May 2013
[Delayed] Surgical Hemostat(TDM-621)Application for CE Marking

16 May 2013
[Delayed] Stock Split and Partial Amendment to the Articles of Incorporation

23 April 2013
Revision of Forecast of Financial Results for FY2012

23 April 2013
Revision of Mid-term Business Plan

21 March 2013
ISO13485 Approval International Standard of Quality Management System

04 February 2013
Surgical Hemostat (TDM-621):IDE Submission to FDA

01 February 2013
Revision of Forecast of Financial Results for FY2012

01 February 2013
Revision of Mid-term Business Plan

20 November 2012
Patent Granted on “Cardiac Tissue Protection and Regeneration” with Self-assembling Peptide Technology

15 November 2012
(Announcement) Subsidiary foundation Completed

16 October 2012
(Announcement) 3-D Matrix Ranked 11th in “Technology Fast50 Japan”

15 October 2012
(Announcement) Subsidiary foundation

25 September 2012
 Semi-exclusive distribution agreement concluded with Fuso Pharmaceutical Industries, Ltd. and Kaken Pharmaceutical Co., Ltd. regarding absorbable local hemostat (TDM-621)

18 September 2012
(Announcement) 3-D Matrix Selected as a Component of J-Stock Index

6 September 2012
Patent Granted on “Modified Peptide” with Self-assembling Peptide Technology

5 September 2012
Patent Granted on “Chondrocyte Cultivation” with Self-assembling Peptide Technology

1 September 2012
(Announcement) Stock Split

17 July 2012
(Announcement) Stock Split and Partial Amendment to the Articles of Incorporation

18 June 2012
Progress report of clinical trial on “Bone Void Filler TDM-711”

17 April 2012
(Announcement) Subsidiary foundation completed

12 April 2012
Notification of Revision to Forecast of Financial Results for the Year Ending April 30, 2012

09 April 2012
Memorandum of Understanding concluded with Fuso Pharmaceutical Industries, Ltd. and Kaken Pharmaceutical Co., Ltd. regarding sales of absorbable local hemostat (TDM-621)

02 March 2012
Clinical study with 3-D Matrix’s technology started at School of Medicine, Keio University

22 February 2012
Clinical trial started in U.S. about dental implant product “Alveolar Rebuilding TDM-711”

20 February 2012
Exclusive distribution license agreement executed with Fuso Pharmaceutical Industries, Ltd. regarding mucous membrane raising device (TDM-641).

17 January 2012
(Announcement) Subsidiary foundation

04 November 2011
3-D Matrix nominated as a joint research partner in Grants-in Aid for Scientific Research Project on triple negative breast cancer treatment.

19 May 2010
Dr. Shuguang Zhang was inducted as a foreign member of Austrian Academy of Sciences on May 19, 2010, in Vienna.

15 Jan 2010
3-D Matrix, Ltd. (Tokyo, Japan) was awarded a prestigious Red Herring Global 100 in recognition of its technology and potential in business. The company was also named Red Herring Asia 100 winner in 2009. 3-D Matrix, Ltd. competed with 300 regional winners from Asia, Europe and North America and was chosen as one of the 100 most promising private companies in the world.

1 May 2008
3-D Matrix, Ltd., Announces Agreement with BD Biosciences to Market Peptide Hydrogel Products to the Global Research Community.

11 October 2007
3-D Matrix, Inc. is acquired by its Japanese collaborator, 3-D Matrix, Ltd., and accelerates its clinical application and research reagent by the support of its new parent company.

1 August 2007
3-D Matrix, Inc to Present at First Albany Capital Regenerative Medicine Conference in NYC

16 July 2007
Robert Langer Wins National Medal of Science

2 April 2007
3-D Matrix, Inc. Technology Named Top Ten Emerging Technologies for 2007 by Technology Review Magazine for Nanohealing

6 September 2006
3-D Matrix, Inc. Welcomes Leading Cardiac and Orthopedic Clinical Researchers to its Clinical Advisory Board

31 July 2006
3-D Matrix, Inc. to Keynote at Dow Jones Wall Street Journal Healthcare Innovations Conference. Demonstrating the Power of Biomaterial Scaffolds in Regenerative Medicine

15 March 2006
3-D Matrix, Inc. to Showcase Next Generation Nanobiomaterials at 2006 Society for Biomaterials & PTEI Regenerative Medicine World Congress

2 November 2005
3-D Matrix, Inc. Founders Awarded $6.5 Million NIH Program Grant for Regenerative Medicine & Tissue Engineering Research

1 August 2005
3-D Matrix, Inc. to Present on Orthopedic Biomaterials at the Dow Jones Venturewire Healthcare Ventures Conference

21 July 2005
BD© PuraMatrix® Synthetic Hydrogels Featured in BD Biosciences Inaugural Web Seminar Series

25 May 2005
3-D Matrix, Inc. to Present Stem Cell Culture Benefits of PuraMatrix® Hydrogels at International Society for Stem Cell Research Conference

21 Feb 2005
3-D Matrix, Inc. Invited to Present on Orthopedic & Cardiac Regeneration at Windhover Convergence: Drug Device Conference

28 Oct 2004
3-D Matrix, Inc. Secures $1.7 Million Financing For Clinical Development of PuraMatrix® Hydrogels

26 Sept 2004
3-D Matrix, Inc. Launches PuraMatrix® Hydrogels Through Worldwide Partnership with BD Biosciences

8 July 2004
PuraMatrix® Hydrogels Win Prestigious R&D100 Life Science Award: Most technologically significant new product impacting medical & life science products launched in the past year

1 March 2004
PuraMatrix® Hydrogels Win International Awards for Biomaterial Nanotechnology & Regenerative Medicine: Most innovative new product to impact biotechnology, drug discovery, and medical devices

9 Dec 2003
3-D Matrix, Inc. Launches PuraMatrix® Synthetic Hydrogels at American Society for Cell Biology “(ASCB) Conference”, Major Advance In 3-D Cell Culture and Defined Drug Discovery Assays

21 Aug 2003
3-D Matrix, Inc. PuraMatrix® Synthetic Extracellular Matrix featured in journal Nature

News

Find out the most recent developments at 3-D Matrix

Learn More

Collaborations

Learn how PuraMatrix® can enhance your technology

Learn More

Publications

Review the strong body of literature utilizing PuraMatrix®

Learn More